Instructions Neogemodez solution for infusions bottle 200 ml
Composition
active ingredients: povidone, sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium bicarbonate;
100 ml of solution contain povidone - 6 g; sodium chloride - 0.55 g; potassium chloride - 0.042 g; calcium chloride dihydrate - 0.0336 g; magnesium chloride hexahydrate - 0.0005 g; sodium bicarbonate - 0.023 g;
ionic composition per 1 ml of the drug: Na+ – 2.22 mg, K+ – 0.22 mg, Ca++ – 0.0913 mg, Mg++ – 0.0006 mg, Cl− – 3.7 mg;
excipient: water for injections.
Dosage form
Solution for infusion.
Main physicochemical properties: clear liquid from pale yellow to yellow; theoretical osmolarity - 212 mosmol/l; pH 5.0–7.0.
Pharmacotherapeutic group
Electrolytes in combination with other drugs. ATX code B05B B04.
Pharmacological properties
Pharmacodynamics
Neogemodesis belongs to plasma-substituting solutions, increases the suspension properties of blood, reduces its viscosity. As a detoxification agent, it binds toxic products in the bloodstream and removes them from the body through the kidneys.
Pharmacokinetics
When administered intravenously, the effect of the drug appears as it enters the bloodstream. The effect lasts for 3–12 hours, depending on the functional state of the kidneys and the speed of blood circulation. It is excreted from the body by the kidneys.
Indication
Detoxification of the body in infectious diseases accompanied by toxicosis; burn disease in the intoxication phase (2–5th day); acute radiation sickness in the intoxication phase; peritonitis and intestinal obstruction (in the pre- and postoperative period); edema caused by chronic kidney disease; thyrotoxicosis; sepsis; liver diseases in the liver failure phase.
Contraindication
Hypersensitivity to the drug (especially a history of reactions to povidone), severe cardiovascular and pulmonary insufficiency, hemorrhagic stroke, bronchial asthma, acute nephritis, acute kidney injury, severe allergic and immunosuppressive conditions.
Incompatibility.
Do not mix with other medicines.
Interaction with other medicinal products and other types of interactions
Not established. No medications should be added to the Neogemodez solution.
Application features
The drug should be administered with caution to patients with impaired renal excretory function. Treatment of severe intoxications should be carried out under the supervision of a physician.
With rapid infusion, arterial hypotension, tachycardia, and difficulty breathing may occur, which requires discontinuation of the drug and the administration of calcium chloride (intravenously), ephedrine, agents that act on the cardiovascular system, and polyglucin.
Ability to influence reaction speed when driving vehicles or other mechanisms
During treatment, you should refrain from driving or operating other mechanisms, as the drug may cause such undesirable effects as dizziness and headache.
Use during pregnancy or breastfeeding
Do not use the drug during pregnancy.
It is not known whether the drug passes into breast milk, so it should not be used during breastfeeding.
Method of administration and doses
The drug is administered intravenously, drip, at a rate of 20–40 drops per minute. Before administration, the solution is heated to 35–37 °C. For adults, a single dose is 400 ml; for children aged 6–9 years - up to 100 ml; for children aged 10–15 years - up to 150 ml.
Repeated infusions of Neogemodez should be carried out according to indications, but not earlier than 10–12 hours after its previous administration. The course of treatment is no more than 5 days.
The administration of the drug, especially in severe conditions of patients, must be carried out under the supervision of a physician.
Children
The drug should be used in children over 6 years of age.
There is no experience with the use of the drug in children under 6 years of age.
Overdose
Symptoms: hyperhydration, hypotension.
Treatment: discontinuation of the drug, if necessary - administration of cardiac drugs, calcium chloride, rheopolyglucin.
Adverse reactions
Immune system disorders: hypersensitivity reactions, anaphylactic shock, angioedema, hyperthermia.
Skin and subcutaneous tissue disorders: pallor of the skin, skin rash, urticaria, hyperemia, maculopapular and petechial rashes, itching.
Cardiovascular system: tachycardia, pain in the heart area, arterial hypotension.
Respiratory system: shortness of breath, bronchospasm.
From the nervous system: headache, dizziness.
From the digestive tract: nausea, vomiting.
On the part of the body as a whole: general weakness, sweating, increased body temperature, chills, changes at the injection site.
Expiration date
3 years.
Storage conditions
Store at a temperature not exceeding 25 °C out of the reach of children.
Packaging
200 ml in bottles.
Vacation category
According to the recipe.
Producer
Private Joint Stock Company "Infusion".
Location of the manufacturer and its business address
Ukraine, 23219, Vinnytsia region, Vinnytsia district, village Vinnytskie Khutory, Nemyrivske highway st., bldg. 84A.
